cyrilzakka/clinical-trials huggingface dataset:
Tension-free Repair of Inguinal Hernia With "Undissociate Spermatic Cord"

The theory of "undissected Spermatic cord (US)" only transected the hernia ring ends in the abdominal cavity, the hernia ring, hernia sac and spermatic cord will not be dissected. Its significance lies in that inguinal hernia repair can get rid of the "entanglement" of hernia sac and spermatic cord and fundamentally change the treatment mode of hernia ring and hernia sac.

In recent years, with the deepening of the anatomical cognition of the inguinal region and the renewal of the hernia repair concept, inguinal hernia repair has become increasingly mature surgical approach. However, no matter how the hernia repair modes change, the treatment and repair of the hernia ring has always been the focus, so that the treatment of the hernia sac has been neglected. From March 2014 to May 2019, there were 132 patients underwent inguinal hernia repair with "Undissociate Spermatic cord" theory (Undissected Spermatic cord and hernia sac, hernia ring and sac exclusion). All the patients were followed up for 18\~63 months (mean of 41.5 months) without recurrence. Its significance lies in that inguinal hernia repair can get rid of the "entanglement" of hernia sac and spermatic cord and fundamentally change the treatment mode of hernia ring and hernia sac.

Eligibility Criteria:
Inclusion Criteria:

* Inguinal hernia patients who can tolerate surgery

Exclusion Criteria:

* Patients who cannot tolerate surgery
Enteral Feeding Study of Formula Containing Fish Oil in Critical Care Setting

The purpose of this study is to evaluate the clinical applicability of an enteral tube feeding formula containing fish oil and prebiotics in a critical care population.

In terms of nutrition support in the acute care setting, it is generally accepted that

1. earlier is better
2. enteral is superior to parenteral
3. the quality of nutrients appears more important than quantity
4. select populations will show additional benefit from specific nutrient supplementation.

The current study is designed to evaluate the tolerance of an enteral formula in trauma and surgery patients, as demonstrated by achieving and maintaining enteral feeding goal, gastrointestinal tolerance and inflammatory markers.

Eligibility Criteria:
Inclusion Criteria:

* 18 - 70 years old
* New ICU admit
* Enteral tube feeding anticipated for at least 7 days
* Informed consent

Exclusion Criteria:

* Enteral tube feeding immediately prior to admit
* Parenteral feeding
* Medical condition that preclude receiving tube feeding or formula
* Determined by PI to be inappropriate
* Participating in another clinical trial
Shockwave Therapy for Acute Low Back Pain

The purpose of this study is to determine whether shockwave therapy is more effective in the treatment of unspecific acute low back pain than sham therapy.

60 patients with acute low back pain will be recruited to a single-blinded, randomized, placebo-controlled trial. They are randomized to receive either shockwave therapy or sham treatment by a identically looking device for 4 weeks, twice a week. Additionally patients receive physiotherapy twice a week and are allowed to take an anti-inflammatory drug, if necessary for even 4 weeks. The primary outcome variable will be measured at day 0, every week during treatment (day 7; 14; 21 and 28) and up to 4 weeks after the last treatment. The clinical outcome will be primarily measured by pain intensity using a visual analogue scale. Secondary outcome measures are Oswestry Disability Index, Beck's Pain Depression Scale, Roland Morris Disability Questionnaire and the EQ-5D. Data will be analysed for the difference in change of scores between groups using one-way t-test.


Eligibility Criteria:
Inclusion Criteria:

low back pain for less than 3 months

Exclusion Criteria:

* Patients with relevant leg pain
* Patients with spine operations in the past
* neurologic symptoms
* scoliosis with Cobb angle \> 10°
* Patients experienced in shock wave therapy
* Patientes with ongoing therapy with blood diluting drugs such as phenprocumon
* Patients with osteoporosis
* Patients with back pain after trauma
* Patients with infective diseases or tumor diseases
* Patients with relevant psychological diseases
Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor

The purpose of this research study is to compare induction of labor using a foley catheter bulb with a low dose of oxytocin versus a foley catheter bulb with an increasing dose of oxytocin. A foley catheter bulb with or without oxytocin is a common method of labor induction in patients whose cervix is not significantly dilated or thinned out (effaced). Oxytocin (pitocin) is a medicine used to increase the number and strength of the womb's contractions.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with a singleton pregnancy
2. Term pregnancy (\> 37 weeks gestation)
3. Age ≥ 18 years
4. Bishop score \< 5
5. Contractions \< 6/hr
6. Reassuring fetal heart tracing

Exclusion Criteria:

1. Rupture of membranes
2. Antepartum bleeding
3. Fetal death
4. Placenta previa or low lying placenta
5. Active genital herpes infection
6. Previous use of an induction or preinduction agent during the current pregnancy
7. EFW \>4500 grams
8. Non reassuring fetal testing
9. Inability to pass foley through cervix
10. Prior cesarean section
Effect of Mouth Rinses in Oral Malodor

Bad breath or halitosis is caused by specific gases originating from the mouth or the expired air. In most cases the pathology lies within the mouth and in this case receives the name pathologic halitosis of oral cause or oral malodor. The aim of this study is to evaluate the immediate (masking) and long term (therapeutic) effect of commercially available mouth rinses in the treatment of oral malodor. For this volunteers with oral malodor detected by organoleptic evaluation and confirmed by the increase level of sulphur compounds in their breath (VSC) will be asked to use a designated mouthwash. The breath parameters will be assessed at baseline and 15' after the first rinse (15 ml, during 1 minute) and over night at the end of a period of 3 weeks during which the volunteers rinsed twice a day (15 ml, 1 minute) with the assigned mouthwash. The short and long term effect of a stannous fluoride/amine fluoride/zinc rinse; a chlorhexidine/cetylpyridinium chloride/zinc product and a negative control(fluoride rinse and/or water) will be compared.


Eligibility Criteria:
Inclusion Criteria:

* Caucasian
* Age ≥ 18 years
* Organoleptic score of breath ≥ 2
* VSC readings (sum of H2S and CH3SH by OralChroma) ≥ 120 ppb\*
* Intra-oral cause of bad breath
* Non-smokers
* Willing to participate and able to give written informed consent

Exclusion Criteria:

* Ongoing dental treatment or any other medical treatment of the oral cavity
* Any known allergy to previously used oral hygiene products or any known allergy to any of the ingredients of the study products, which are used during the study
* Any pathological change of the oral mucosa
* Use of prohibited treatments / therapies and/or abuse of drugs, alcohol, etc
* Pregnancy or breastfeeding
* Active caries
* Acute sinusitis
* Severe oro-pharyngeal infections
* On medications which can cause malodour
* Reduced salivary flow due to pathological reasons (e.g. Sjögren syndrome)
* Situation considered not compatible with the study according to the investigator's opinion; the latter includes: patients eating very spicy food, persons under homeopathic therapy, patients who used antibiotics during the 2 months before the study, patients frequently using chewing gum, patients under corticosteroids or other serious medications.
* Patients unwilling to abstain from additional oral hygiene (only toothbrushing allowed) particularly mouthrinse, chewing gums, breath strips, etc
Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis

The ultrasound-guided biopsies of the prostate is the validated technique for the diagnosis of prostate cancer, the first human cancer and second leading cause of cancer death. Overall, in more than half of cases, prostate biopsies performed in search of a prostate cancer are negative. In this population, there is no consensus recommendation on how to care, leading to repeated invasive biopsies, potential sources of complications.

The PCA3 urine test (ProgensaTM, GenProbe) is an innovative diagnostic tool to predict the positivity of prostate biopsies, especially in patients who had at least one negative biopsy. Proposed in clinical practice in France as a commercial kit, it is expensive and is not covered by health insurance. It is therefore essential to assess the medical and economic impact of its introduction into medical practice.

The investigators propose to set up a study of high standard of proof, multicenter, based on recruitment of patients treated in hospitals. This working hypothesis is that the availability of the PCA3 test results would reduce the number of invasive biopsies performed incorrectly in patients already had at least one negative biopsy, thus improving the diagnostic strategy of prostate cancer.


Eligibility Criteria:
Inclusion Criteria:

* patients ≥ 18 year-old
* patients who undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination
* patients who gave informed consent

Exclusion Criteria:

* no informed consent
* medical history of or current significant prostate cancer
* medical history of or current extra-prostatic cancer
* high risk of loss of follow-up
* clinically obvious prostate cancer (clinical stage ≥ T3, PSA ≥ 50 ng/ml, lymph node involvement, osteolytic bone metastases)
Evidence of Myogenic Growth Factors in 3D Dynamic Inguinal Hernia Scaffold ProFlor

The study utilizes the same tissue specimens gathered for previous investigations and removed from 15 patients already operated for inguinal hernia, who for different reasons needed additional surgery in the previously operated groin.

Among the individual of investigated the cohort, seven patients underwent groin revision for subsequent hydrocele, 4 for recurrence, and 4 for overlooked ipsilateral multiple hernia protrusions. Made from low weight, large porous polypropylene, ProFlor is composed of a multilamellar cylindrical 3D core, 15 mm thick, with 2 different longitudinal dimensions, 25 or 40 mm. The center of the implant core is connected on one surface to a flat mesh of different width depending on the dimension of the 3D core. This flat part of the device is intended to be deployed to counterface the peritoneal sheath. The 3D core of ProFlor ® is arranged to be compressible on both planes, longitudinal and transversal. Due to its proprietary centrifugal expansion, it can be positioned, fixation free, into the hernia defect for permanent obliteration. ProFlor owns an inherent dynamic responsivity as it contracts and relaxes in accord to the movements of the inguinal floor in which is positioned.

The biopsies were excised from the anterior aspect of the 3D device. It should be noted that once deployed the anterior surface of ProFlor merely faces the external oblique fascia and has no contact with other structures of the groin. Therefore, corruption by host native tissue can be excluded. The biopsies were carried out in ten patients, three in the short term postop. between 3 and 5 weeks, five in the mid-term between 3 and 4 months postop., four in the long-term between 6 and 8 months postop. and the latter three in the extra-long term postop., more than three years after implantation.

Eligibility Criteria:
Inclusion Criteria:

* patients already operated for inguinal hernia with ProFlor, who for different reasons needed additional surgery in the previously operated groin
* ASA score \>4

Exclusion Criteria:

* Patients who do not underwent inguinal hernia repair with ProFlor
Comparison of MORbidity of Submucosal DIssection Resection of Giant cOlon Lesions Versus Surgery: a National Multicenter Study (MORDIGO)

Propose a one-piece endoscopic resection such as endoscopic submucosal dissection (ESD) rather than surgery for benign lesions and superficial T1 cancers colorectal cancers offers comparable efficacy with better tolerability. This approach is all the more in the rectum, even for giant lesions lesions (over 8cm), as rectal surgery is particularly morbid, with particularly morbid, with a functional impact that can impact, whereas rectal ESD is less prone to complications fewer complications than in the colon. Colonic ESD for giant lesions is a longer and more morbid more time-consuming and morbid than for smaller lesions, the question of colonic surgery in this indication. this indication. In order to compare the morbidity data of patients of giant lesions with those of colectomy, a control group colectomy, a surgical control group will be set up, including patients including patients having undergone surgery for in situ T1 or T2 in situ colon cancer. Surgical resections of resection of benign lesions is generally not indicated not indicated and would not provide the necessary necessary for a comparison. T3 and T4 lesions with their own their own morbidity will be excluded.


Eligibility Criteria:
Inclusion Criteria:

* Group A :
* Patients from the FECCO cohort
* who have undergone ESDresection of a giant lesion, defined by a fresh specimen measuring more than 8cm long axis, of the colon
* Between September 2019 and 2022
* Major
* Patient affiliated to a social security scheme

Group B:

* Patients from the Registre des Tumeurs Digestives Registry (Brest University Hospital)
* Having undergone colectomy with lymph node dissection for intramucosal colonic adenocarcinoma, T1 or T2 colonic adenocarcinoma
* Between September 2019 and 2022
* Adults
* patient affiliated to a social security scheme

Exclusion Criteria:

* - rectal lesion ;
* patients under legal protection (guardianship, curatorship,

  ...) or deprived of liberty ;
* refusal to participate.
Bariatric Surgery and Pharmacokinetics of Buprenorphine

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on buprenorphine are investigated.


Eligibility Criteria:
Inclusion Criteria:

* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway
* Being a Norwegian citizen

Exclusion Criteria:

* Having previously undergone resections in the GI-tract
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma

This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.

Eligibility Criteria:
Inclusion Criteria:

* Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
* Treatment naive
* Age ≥ 18 years
* Indications for treatment confirmed
* Must has measurable lesion in CT or PET-CT prior to treatment
* Considered suitable for GR, GB or GCHOP regimens
* Informed consented

Exclusion Criteria:

* Transformed follicular lymphoma or 3B follicular lymphoma;
* HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive
* Central nervous system or meninges involved
* Any drug contraindication in the treatment plan
* Patients judged by other researchers to be unsuitable for inclusion in the study
Sagittal Imbalance and Lumbar Stenosis Surgery: Decompression Without Implant

Lumbar stenosis (LSS) is the most frequent degenerative lumbar disease and is the most frequent indication for spinal surgery. When non-invasive treatments fail, decompression surgery is the gold standard therapy for the majority of patients and generally improves symptoms.

However, few studies have investigated the improvement in posture (radiological parameters) after surgery. In lumbar stenosis, patients may present a forward leaning posture (to relieve pain), which is responsible for sagittal imbalance.

The aim of this prospective study was to evaluate the repercussions of decompression surgery on sagittal balance and to compare these with aux clinical results. investigators included patients operated on for isolated lumbar canal stenosis.


Eligibility Criteria:
Inclusion Criteria:

1. Symptoms and signs of neurogenic claudication and radiological signs of central lumbar stenosis;
2. Patients undergoing open decompression surgery ≤ 3 levels,
3. All patients with symptoms that did not respond to at least 3 months of non-invasive treatment.

Exclusion Criteria:

Patients were excluded from the study if they had one or several of the following clinical and/or radiological criteria:

1. spondylolisthesis (disc slip \> 5 mm),
2. criteria showing instability (variation of \> 10° in the angle formed by the vertebral endplates on dynamic images).
3. scoliosis (Cobb angle \> 20 °).
4. Patients lost to follow-up were excluded.
Metoclopramide in Upper Gastrointestinal Bleed

The goal of this clinical trial is to test if metoclopramide can improve effectiveness of endoscopic intervention in upper gastrointestinal (GI) bleeds. The main questions the investigators hope to answer is

Does metoclopramide lessen the need for repeat endoscopy, interventional radiology intervention or surgery in cases of upper GI bleed?

Does metoclopramide improve visibility of the GI walls in cases of upper GI bleed?

The purpose of the study is to see if giving metoclopramide prior to an endoscopy in cases of upper GI bleed can decrease the need for repeat endoscopy due to poor visibility. Metoclopramide stimulates stomach and intestine activity. It is used to treat nausea, vomiting and slow gut movement. The investigators are testing if metoclopramide's effect on stimulating stomach activity can lead to more effective emptying of blood from the stomach and upper intestines in upper GI bleeding so physicians conducting endoscopies can easily see the stomach and intestinal wall and treat the source of bleeding.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 and above
* Admitted to ER or inpatient services at Javon Bea Hospital MercyHealth Riverside
* Present with upper GI bleeding defined as fresh and bright red hematemesis, coffee-ground hematemesis or melena
* Plan to undergo EGD within 24 hours since admission or since first symptoms
* Calculated Glasgow-Blatchford score ≥ 2

Exclusion Criteria:

* Failure to obtain informed consent
* Known allergy to metoclopramide
* Concurrent use of medications known to cause tardive dyskinesia (TD)/extrapyramidal symptoms/neuroleptic malignant syndrome
* History of TD or dystonic reaction to metoclopramide
* Pheochromocytoma, catecholamine-releasing paragangliomas
* Parkinson's Disease
* Epilepsy
* Pregnancy or lactation
* Previous gastrectomy
To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions

To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets under Fasting Conditions.


Eligibility Criteria:
Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
Blood Pressure Target in Acute Stroke to Reduce hemorrhaGe After Endovascular Therapy

A randomized, multicenter study comparing two strategies: 1 / standard management of systolic blood pressure according to international recommendations (systolic blood pressure \<185 mm Hg) versus 2 / intensive blood pressure management Systolic with a target \<130 mm Hg.

Patients will be followed for 3 months:

* inclusion after reperfusion: clinical evaluation with NIHSS (National Institute of Health Stroke Score) score, measurement of blood pressure.
* within 24 hours after reperfusion: blood pressure measurements
* at 24 hours: measurement of blood pressure (T0 + 24 h and evaluation of the NIHSS score.
* Between 24 and 36 hours :cerebral scan (assessment of hemorrhagic transformations and cerebral infarction volumes). For some centers: Cerebral MRI without injection between H24 and H36
* 72 hours after reperfusion: Cerebral scanner in case of hyperdensity on the initial scanner
* 3 months after reperfusion: disability assessment by Rankin score

Eligibility Criteria:
Inclusion Criteria:

* Intracranial Occlusion of internal carotid arteries and/or proximal middle cerebral (segment M1) diagnosis made on initial Imaging.
* Reperfusion after a thrombectomy procedure (defined by a 2b-3 TICI score -Thrombolysis In Cerebral Infarction- score).

Exclusion Criteria:

* Per-procedure hemorrhagic complications (prior to reperfusion)
* Systolic blood pressure at baseline \<130 mm Hg within one hour of recanalization
* Pre-existing stroke handicap defined by a Rankin score (modified scale, mRS)\> 3
* Hemodynamically significant carotid stenosis
* Occlusion of the isolated cervical carotid artery
* Known pregnancy
* Legal protection
* Non-affiliation to a social security scheme
* Refusal of the patient (or of his / her relatives in case of urgent inclusion)
App Delivered Brief Mindfulness Intervention for Surgical Patients

This will be a single-site, five-arm, parallel group randomized control trial involving patients undergoing knee or hip replacement surgery. The investigators will compare five different styles of 5-minute, audio-recoded mindfulness practices delivered via app 7 days before to surgery, 2 days before to surgery, 2 days after surgery, and 6 days after surgery.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18,
* Scheduled to undergo total joint arthroplasty of the knee or hip

Exclusion Criteria:

* Inability to read English
* Cognitive impairment preventing completion of study procedures
Brain Stimulation & Generalized Anxiety Study

Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.


Eligibility Criteria:
Inclusion Criteria:

* Age greater than 21
* US resident
* Can receive packages to their home via UPS/Fedex/USPS
* Licensed Physician Diagnosis of Generalized Anxiety Disorder
* Beck Anxiety Inventory Score between 8 and 25
* Read/write English
* Have not contemplated suicide in the past year
* Not been institutionalized for mental health issues.
* Not currently experiencing problems with alcohol or drug abuse
* Can commit to not drinking alcohol 4 hours before bedtime for the duration of the study
* Can commit to two (2) 20 minute sessions per day for 8 weeks
* Not under medical supervision for serious medical condition
* Not currently being treated for or suspect a mental health issue
* Has not used a brain stimulation treatment in one year
* No suspected or known history of heart disease
* No pacemaker, or any form of medical electronics, including but not limited to a deep - brain stimulator, electronic stent, etc.
* Not taking opioids
* Are a resident of states in which we have licensed medical professionals
* Does not have any co-occurring significant psychiatric disorder that would impair - participant's particationion.
* Does not use any illicit drugs
* Not participating in any other anxiety study
* Not taking medications affecting the nervous system (e.g. psychiatric medications)
* Not taking hypnotics or any sleep aid or marijuana (in any form)